相关临床试验
0
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Catalyst Pharmaceuticals and SERB S.A. have settled patent litigation with Hetero Labs Ltd., preventing generic competition for FIRDAPSE until January 2035. - The settlement resolves all pending FIRDAPSE patent litigation, following previous agreements with Lupin Pharmaceuticals, Teva Pharmaceuticals, and Inventia Healthcare Limited. - FIRDAPSE, approved for Lambert-Eaton Myasthenic Syndrome, continues to drive Catalyst's record financial performance with Q2 2025 revenues reaching $146.6 million, up 19.4% year-over-year. - Analysts maintain unanimous Strong Buy ratings with an average price target of $34, representing over 60% upside potential from current trading levels around $21.
- Lupin's Phase 3 trial demonstrated that single-dose Solosec (secnidazole) achieved a 92-95% microbiological cure rate in female patients with trichomoniasis versus 1.5-1.7% with placebo. - The company plans to submit a supplemental New Drug Application to the FDA later this year to expand Solosec's indication beyond bacterial vaginosis to include trichomoniasis treatment. - Trichomoniasis affects an estimated 3-5 million people in the U.S. and is the most common non-viral, curable sexually transmitted infection, with African American women facing nearly ten times higher risk. - The single-dose oral treatment could address compliance challenges in treating this infection, which increases HIV risk and can lead to adverse reproductive health outcomes if left untreated.
- Catalyst Pharmaceuticals and SERB S.A. reached a settlement agreement with Lupin that prevents generic competition for FIRDAPSE (amifampridine) until February 25, 2035. - The settlement resolves patent litigation stemming from Lupin's attempt to market a generic version of the rare disease treatment before patent expiration. - Catalyst has now settled similar patent disputes with Teva Pharmaceuticals and Inventia Life Science, with ongoing litigation against Hetero remaining. - The agreement ensures continued market exclusivity for FIRDAPSE, a treatment for patients with rare and difficult-to-treat diseases, extending commercial protection by over a decade.
- Saniona announced a licensing agreement with Jazz Pharmaceuticals worth up to $1 billion, representing one of the largest pharmaceutical patent deals in recent weeks. - The pharmaceutical industry has dominated patent licensing activity, with multiple billion-dollar agreements including Bayer's $1.3 billion deal with Kumquat Biosciences for cancer treatment licensing. - BioNTech and GSK also completed a significant $500 million mRNA vaccine patent deal and settlement of infringement litigation during this period. - Patent litigation settlements continue to shape the industry landscape, with companies like Catalyst and Lupin Pharmaceuticals resolving disputes through licensing agreements.
- The FDA approved 25 first-time generic drugs in the first six months of 2025, including generics for critical medications treating HIV, cancer, and neurological conditions. - Notable approvals include generic versions of Xarelto (rivaroxaban) for blood clot prevention, Complera for HIV treatment, and Fycompa (perampanel) for seizure management. - These generic approvals span diverse therapeutic areas from oncology to ophthalmology, potentially reducing healthcare costs while maintaining equivalent clinical benefits to brand-name products.
